background:
May negatively regulate cell cycle progression. May act at least in part via inhibition of the cyclin-D1/CDK4 complex, thereby preventing phosphorylation of RB1 and blocking E2F-dependent transcription.
Tissue specificity: Ubiquitously expressed. Expression is down-regulated in a variety of tumor types including breast, colon, prostate and rectal tumors, and is up-regulated in certain hepatic carcinomas.
Function:
May negatively regulate cell cycle progression. May actat least in part via inhibition of the cyclin-D1/CDK4 complex,thereby preventing phosphorylation of RB1 and blockingE2F-dependent transcription.
Subunit:
Interacts with CCND1 and GRAP2. May also interact withCOPS5, RPLP0, SIRT6, SYF2 and TCF3.
Subcellular Location:
Cytoplasm. Nucleus.
Tissue Specificity:
Ubiquitously expressed. Expression isdown-regulated in a variety of tumor types including breast, colon,prostate and rectal tumors, and is up-regulated in certain hepaticcarcinomas.
Post-translational modifications:
Phosphorylated.
Similarity:
Belongs to the CCNDBP1 family.
Database links:
UniProtKB/Swiss-Prot: O95273.2
Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
|
|